» Articles » PMID: 7877454

Gene Expression of GLUT3 and GLUT1 Glucose Transporters in Human Brain Tumors

Overview
Date 1994 Nov 1
PMID 7877454
Citations 56
Authors
Affiliations
Soon will be listed here.
Abstract

GLUT3 glucose transporter gene expression is confined to neurons, while GLUT1 gene expression is limited to endothelial cells in normal brain. Thus far, neither of the GLUT genes has been shown to be consistently expressed in glial cells in adult brain in vivo under normal conditions. However, GLUT gene expression may be aberrant in human brain glial tumors. The present investigation shows that the GLUT1 and GLUT3 transcripts are differentially expressed in a series of 20 human brain tumors. The GLUT1/actin mRNA ratio increased in parallel to the astrocytoma grade, compared to a control human brain cortex, although no change in this ratio was seen in 5 meningiomas. Immunoreactive GLUT1 protein was not detectable in human brain tumors, including high-grade gliomas. Both 4.2 or 2.7 kb GLUT3/actin mRNA ratios showed a linear correlation with the glioma grade (P < 0.025), and the GLUT3-immunoreactive protein was also expressed in high grade gliomas. These studies provide evidence for induction of GLUT1 and GLUT3 gene expression in malignant glial cells, and the mRNA levels correlate with the biologic aggressiveness of the tumor. The detection of immunoreactive GLUT3, but not GLUT1, in the high grade gliomas suggest the GLUT3 isoform may be the predominant glucose transporter in highly malignant glial cells of human brain.

Citing Articles

Molecular Profiling of Glioblastoma Patient-Derived Single Cells Using Combined MALDI-MSI and MALDI-IHC.

Krestensen K, Hendriks T, Grgic A, Derweduwe M, De Smet F, Heeren R Anal Chem. 2025; 97(7):3846-3854.

PMID: 39932302 PMC: 11866282. DOI: 10.1021/acs.analchem.4c03821.


Dynamic glucose-enhanced MRI of gliomas: A preliminary clinical application.

Mo J, Xu X, Ma A, Lu M, Wang X, Rui Q NMR Biomed. 2024; 38(1):e5265.

PMID: 39500570 PMC: 11604297. DOI: 10.1002/nbm.5265.


Targeting the Leloir Pathway with Galactose-Based Antimetabolites in Glioblastoma.

Sharpe M, Ijare O, Raghavan S, Baskin A, Baskin B, Baskin D Cancers (Basel). 2024; 16(20).

PMID: 39456605 PMC: 11506710. DOI: 10.3390/cancers16203510.


Envisioning Glucose Transporters (GLUTs and SGLTs) as Novel Intervention against Cancer: Drug Discovery Perspective and Targeting Approach.

Shafi S, Ahmed Khan M, Ahmad J, Rabbani S, Singh S, Najmi A Curr Drug Targets. 2024; 26(2):109-131.

PMID: 39377414 DOI: 10.2174/0113894501335877240926101134.


Metabolic Roles of HIF1, c-Myc, and p53 in Glioma Cells.

Trejo-Solis C, Castillo-Rodriguez R, Serrano-Garcia N, Silva-Adaya D, Vargas-Cruz S, Chavez-Cortez E Metabolites. 2024; 14(5).

PMID: 38786726 PMC: 11122955. DOI: 10.3390/metabo14050249.